EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Association Between Differences in Estimated GFR by Creatinine Vs. Cystatin C and Stroke Outcomes: Results From the Third China National Stroke Registry

Zusammenhang zwischen Unterschieden der geschätzten GFR nach Kreatinin versus Cystatin C und Schlaganfall-Outcomes: Ergebnisse aus dem Third China National Stroke Registry

Qi Huang iD, Yuesong Pan iD, Hongyi Yan, Xia Meng iD, Yin Zhang, Mengxing Wang, Anxin Wang iD, Yilun Zhou iD, Yongjun Wang iD

CNS Neuroscience & Therapeutics · 2026-05 · 32 (5)

DOI: 10.1002/cns.70930 ↗

Auf einen Blick

Bei 10.293 Personen mit ischämischem Schlaganfall oder transitorischer ischämischer Attacke waren größere Unterschiede zwischen eGFRcys und eGFRcr mit mehr Behinderung und Mortalität assoziiert.

Fragestellung

Ist der Unterschied zwischen cystatin C- und kreatininbasierter eGFR mit dem Schlaganfallprognose verknüpft?

Methode

Multizentrische, prospektive Kohortenstudie aus dem Third China National Stroke Registry; Analyse von eGFRabdiff, eGFRrediff und ΔeGFRdiff; Outcomes über 5 Jahre.

Ergebnisse

eGFRabdiff < −15 mL/min/1,73 m² war mit Behinderung (OR 1,19; 95 %-KI 1,05–1,35) und Mortalität (HR 1,28; 95 %-KI 1,12–1,46) assoziiert. eGFRrediff < 0,6: Behinderung OR 1,66 (95 %-KI 1,25–2,19), Mortalität HR 1,49 (95 %-KI 1,17–1,90).

Schlussfolgerung der Autor:innen

Signifikante und zunehmende eGFRdiff waren unabhängig mit einem erhöhten Risiko für post-stroke Behinderung und Mortalität assoziiert. Das unterstreicht die Bedeutung der Überwachung von eGFRcys und eGFRcr in der Schlaganfallbehandlung.

Kernaussagen

  • eGFRabdiff < −15 war mit mehr Behinderung und Mortalität assoziiert
  • eGFRrediff < 0,6 zeigte ebenfalls höhere Risiken
  • Größere Veränderungen von eGFRdiff gingen mit höherer Mortalität einher

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 18.05.2026. Verfasst von Qi Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Cystatin C, Glomerular Filtration Rate, Creatinine, Stroke. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital's Funds for Health Improvement and Research, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The effect of the difference between cystatin C‐ and creatinine‐based estimated glomerular filtration rates (eGFRdiff) on stroke outcomes is unclear. This study investigated the association between eGFRdiff and stroke prognosis.

Methods

Participants with ischaemic stroke or transient ischaemic attack were recruited from the Third China National Stroke Registry, a multicenter, prospective cohort. eGFRdiff was calculated using the absolute difference (eGFRabdiff defined as cystatin C‐based (eGFRcys) minus creatinine‐based (eGFRcr)) and the ratio (eGFRrediff) between eGFRcys and eGFRcr estimates. eGFRabdiff (< −15, −15–15, ≥ 15 mL/min/1.73 m 2 ) and eGFRrediff (< 0.6, ≥ 0.6) were analyzed. Time‐updated eGFRdiff (ΔeGFRdiff) was defined as the change from baseline to 1‐year blood re‐examination and tertiled. Outcomes included 5‐year all‐cause mortality, stroke disability, and stroke recurrence.

Results

Among 10,293 participants, 35.2% had an eGFRabdiff < −15 mL/min/1.73 m 2 , and 3.5% had an eGFRrediff < 0.6. Compared with midrange eGFRabdiff, participants with eGFRabdiff < −15 mL/min/1.73 m 2 had an odds ratio (OR) of 1.19 (95% confidence interval (CI), 1.05–1.35) for disability and a hazard ratio (HR) of 1.28 (95% CI, 1.12–1.46) for mortality. eGFRrediff < 0.6 was associated with a higher risk for disability (OR, 1.66; 95% CI, 1.25–2.19) and mortality (HR, 1.49; 95% CI, 1.17–1.90). Participants with the largest ΔeGFRdiff declines had higher mortality (OR, 1.44; 95% CI, 1.14–1.82) and borderline disability risk significance (HR, 1.25; 95% CI, 0.96–1.61).

Conclusions

Significant and widening eGFRdiff were independently associated with increased risks of post‐stroke disability and mortality, highlighting the importance of monitoring eGFRcys and eGFRcr in stroke management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystatin CGlomerular Filtration RateCreatinineStrokeHumansFemaleMaleRegistriesChinaAgedMiddle AgedProspective StudiesPrognosisCohort Studies

Stichwörter der Autor:innen

creatininecystatin Cglomerular filtration rateprognosisstroke

Substanzen

Cystatin CCreatinine

Autor:innen und Institutionen

  • Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.
  • Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • China National Clinical Research Center for Neurological Diseases, Beijing, China.
  • Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China.
  • Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China.

ORCID-Profile: Qi Huang, Yuesong Pan, Xia Meng, Anxin Wang, Yilun Zhou, Yongjun Wang

Förderung

  • Capital's Funds for Health Improvement and Research
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China
  • Beijing Municipal Administration of Hospitals Incubating Program

Zitieren

APA

Huang, Q., Pan, Y., Yan, H., Meng, X., Zhang, Y., Wang, M., Wang, A., Zhou, Y., & Wang, Y. (2026). Association Between Differences in Estimated GFR by Creatinine Vs. Cystatin C and Stroke Outcomes: Results From the Third China National Stroke Registry. CNS Neuroscience & Therapeutics, 32(5). https://doi.org/10.1002/cns.70930

Vancouver

Huang Q, Pan Y, Yan H, Meng X, Zhang Y, Wang M, et al. Association Between Differences in Estimated GFR by Creatinine Vs. Cystatin C and Stroke Outcomes: Results From the Third China National Stroke Registry. CNS Neuroscience & Therapeutics. 2026;32(5). doi:10.1002/cns.70930

BibTeX
@article{Huang2026,
  author = {Huang, Qi and Pan, Yuesong and Yan, Hongyi and Meng, Xia and Zhang, Yin and Wang, Mengxing and Wang, Anxin and Zhou, Yilun and Wang, Yongjun},
  title = {Association Between Differences in Estimated GFR by Creatinine Vs. Cystatin C and Stroke Outcomes: Results From the Third China National Stroke Registry},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {5},
  doi = {10.1002/cns.70930}
}
Kostenlos starten →